USPSTF updates recommendations for aspirin use
The U.S. Preventive Services Task Force (USPSTF) recommends aspirin for primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) in some high-risk adults in their 50s and 60s. The guidelines, which update the group's 2007 and 2009 recommendations, are published in the Annals of Internal Medicine. To support the revisions, the USPSTF reviewed five additional studies of aspirin for the primary prevention of CVD and several additional analyses of CRC follow-up data.
Highlights of the new recommendations include the following.
* Low-dose aspirin is recommended for adults aged 50-59 who have at least a 10% risk for a cardiovascular event in the next decade, low bleeding risk, and a life expectancy of at least 10 years; patients must also be willing to take aspirin daily for at least 10 years (grade B recommendation).
* For adults aged 60-69 fitting the above criteria, the decision to start aspirin should be an individual one (grade C).
* For patients younger than 50 and older than 69, there is not enough evidence to make recommendations (grade I).
Source: Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2016. Published online April 12, 2016.
Ticagrelor no better than aspirin for CVD prevention
The antiplatelet ticagrelor (Brilinta; AstraZeneca) is no better than aspirin for preventing cardiovascular events in patients with acute ischemic stroke or transient ischemic attack, the manufacturer has announced.
In the international SOCRATES trial, adults ages 40 and older who had had a stroke or TIA within the past 24 hours were randomized to receive ticagrelor (90 mg twice daily) or aspirin (100 mg once daily) for 90 days. The primary efficacy endpoint was the time to first occurrence of stroke (ischemic or hemorrhagic), myocardial infarction, or death.
The manufacturer said that while fewer endpoint events occurred with ticagrelor, the difference between groups was not statistically significant.
Source: News release. "AstraZeneca reports top-line results from the Brilinta SOCRATES trial in stroke." http://bit.ly/ticagreloraspirin. Accessed May 4, 2016.